Tanja Gatard

Sequential administration of a MVA-based MUC1 cancer vaccine and the TLR9 ligand Litenimod (Li28) improves local immune defense against tumors.

K. Rittner, A. Carpentier, C. Jakobs, 2017, Vaccine.

HLA-A*01:03, HLA-A*24:02, HLA-B*08:01, HLA-B*27:05, HLA-B*35:01, HLA-B*44:02, and HLA-C*07:01 Monochain Transgenic/H-2 Class I Null Mice: Novel Versatile Preclinical Models of Human T Cell Responses

S. Buus, L. BenMohamed, F. Lemonnier, 2013, The Journal of Immunology.

ResponsesPreclinical Models of Human T Cell Transgenic/H-2 Class I Null Mice: Novel and HLA-C*07:01 Monochain HLA-B*27:05, HLA-B*35:01, HLA-B*44:02, HLA-A*01:03, HLA-A*24:02, HLA-B*08:01,

S. Buus, A. Lim, M. Bérard, 2013 .

Responses Versatile Preclinical Models of Human T Cell Hla-a*01:03, Hla-a*24:02, Hla-b*08:01

S. Buus, L. BenMohamed, F. Lemonnier, 2022 .

HLA-A*01:03, HLA-A*24:02, HLA-B*08:01, HLA-B*27:05, HLA-B*35:01, HLA-B*44:02, and HLA-C*07:01 Monochain Transgenic/H-2 Class I Null Mice: Novel Versatile Preclinical Models of Human T Cell Responses

S. Buus, L. BenMohamed, F. Lemonnier, 2013, The Journal of Immunology.